Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Philip M Potter

Showing results (1-10 of 87) with videos related to

Pageof 9
Sort By:
Current Hematology Reports|July 13, 2005
Update on gene therapy approaches for cancerMonika Wierdl, Philip M Potter
Drug Discovery Today|March 8, 2005
Mammalian carboxylesterases: from drug targets to protein therapeuticsMatthew R Redinbo, Philip M Potter
Current Medicinal Chemistry|April 14, 2006
Carboxylesterases--detoxifying enzymes and targets for drug therapyPhilip M Potter, Randy M Wadkins
Expert Opinion on Therapeutic Patents|May 26, 2011
Carboxylesterase inhibitorsM Jason Hatfield, Philip M Potter
Methods in Molecular Medicine|December 6, 2003
Enzyme-prodrug systems: carboxylesterase/CPT-11Mary K Danks, Philip M Potter
Drug Discovery Today|August 14, 2012
The development and application of small molecule modulators of SF3b as therapeutic agents for cancerThomas R Webb, Amanda S Joyner, Philip M Potter
Current Medicinal Chemistry. Anti-Cancer Agents|March 22, 2005
Development of prodrugs for enzyme-mediated, tumor-selective therapyK Jin Yoon, Philip M Potter, Mary K Danks
British Journal of Pharmacology|July 17, 2016
Tumour-selective targeting of drug metabolizing enzymes to treat metastatic cancerMonika Wierdl, Lyudmila Tsurkan, M Jason Hatfield, et al.
Expert Opinion on Drug Metabolism & Toxicology|August 30, 2008
Modifications of human carboxylesterase for improved prodrug activationJason M Hatfield, Monika Wierdl, Randy M Wadkins, et al.
Journal of Pest Science|March 15, 2013
In Silico Design and Evaluation of Carboxylesterase InhibitorsShana V Stoddard, Xiaozhen Yu, Philip M Potter, et al.
Pageof 9

Showing results (1-10 of 87) with videos related to

Sort By:
Pageof 9
Current Hematology Reports|July 13, 2005
Update on gene therapy approaches for cancerMonika Wierdl, Philip M Potter
Drug Discovery Today|March 8, 2005
Mammalian carboxylesterases: from drug targets to protein therapeuticsMatthew R Redinbo, Philip M Potter
Current Medicinal Chemistry|April 14, 2006
Carboxylesterases--detoxifying enzymes and targets for drug therapyPhilip M Potter, Randy M Wadkins
Expert Opinion on Therapeutic Patents|May 26, 2011
Carboxylesterase inhibitorsM Jason Hatfield, Philip M Potter
Methods in Molecular Medicine|December 6, 2003
Enzyme-prodrug systems: carboxylesterase/CPT-11Mary K Danks, Philip M Potter
Drug Discovery Today|August 14, 2012
The development and application of small molecule modulators of SF3b as therapeutic agents for cancerThomas R Webb, Amanda S Joyner, Philip M Potter
Current Medicinal Chemistry. Anti-Cancer Agents|March 22, 2005
Development of prodrugs for enzyme-mediated, tumor-selective therapyK Jin Yoon, Philip M Potter, Mary K Danks
British Journal of Pharmacology|July 17, 2016
Tumour-selective targeting of drug metabolizing enzymes to treat metastatic cancerMonika Wierdl, Lyudmila Tsurkan, M Jason Hatfield, et al.
Expert Opinion on Drug Metabolism & Toxicology|August 30, 2008
Modifications of human carboxylesterase for improved prodrug activationJason M Hatfield, Monika Wierdl, Randy M Wadkins, et al.
Journal of Pest Science|March 15, 2013
In Silico Design and Evaluation of Carboxylesterase InhibitorsShana V Stoddard, Xiaozhen Yu, Philip M Potter, et al.
Pageof 9